Mitochondrial-associated Mechanisms of Neuropathological and Immunodeficient Aging in the Context of HIV and SUD (R21 Clinical Trials Not Allowed)
ID: 356597Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mitochondrial-associated Mechanisms of Neuropathological and Immunodeficient Aging in the Context of HIV and SUD (R21 Clinical Trials Not Allowed)." This initiative aims to support exploratory research projects that investigate the intersection of mitochondrial function, aging, HIV infection, and substance use disorders (SUD), with the goal of informing targeted therapies to improve health outcomes for affected individuals. The total funding available for this opportunity is $3,000,000, with individual project budgets capped at $275,000 for a maximum duration of two years. Applications will be accepted starting February 10, 2025, with a submission deadline of March 10, 2026. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-010.html.

    Point(s) of Contact
    Files
    Title
    Posted
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA), has announced a funding opportunity (RFA-DA-26-010) focused on exploring mitochondrial-associated mechanisms of neuropathological and immunodeficient aging in individuals affected by HIV and substance use disorders (SUD). Utilizing the R21 Exploratory/Developmental Research Grant mechanism, this initiative seeks to support early-stage projects that investigate how mitochondrial function intersects with aging among this population, aiming to inform targeted therapies for improved health outcomes. Applicants are required to develop a Plan for Enhancing Diverse Perspectives (PEDP), emphasizing inclusivity throughout the research process. The total funding available for the project period is $3,000,000, with individual project budgets capped at $275,000 for a maximum of two years. Key dates include an open submission date starting February 10, 2025, with applications due by 5:00 PM local time. The program actively encourages diverse applicants, especially from historically underrepresented groups, thereby fostering innovation in the research arena on aging, HIV, and SUDs.
    Similar Opportunities
    Mitochondrial-associated Mechanisms of Neuropathological and Immunodeficient Aging in the Context of HIV and SUD (R01 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Mitochondrial-associated Mechanisms of Neuropathological and Immunodeficient Aging in the Context of HIV and SUD," aimed at researching the interplay between mitochondrial function, aging, HIV infection, and substance use disorders (SUD). This initiative seeks to uncover protective and pathogenic mechanisms that could lead to the development of targeted therapies to improve health outcomes for individuals aging with HIV and addiction issues. Approximately $3 million in funding is available, with anticipated awards ranging from three to six grants, and a Plan for Enhancing Diverse Perspectives (PEDP) is required from applicants. The application process will commence in February 2025, with a submission deadline of March 10, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-009.html.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Multidisciplinary Studies of HIV/AIDS and Aging," aimed at exploring the intersection of HIV and aging. This initiative seeks to enhance understanding of the biological, clinical, and socio-behavioral aspects of aging in the context of HIV infection, while also improving strategies for testing, prevention, and treatment of HIV-related health complications. Given the increasing number of older adults living with HIV, this research is crucial for addressing public health challenges and improving healthcare delivery across diverse populations. The funding supports exploratory research under the R21 mechanism, with a maximum budget of $275,000 for two years, and applications are due between May 2025 and January 2027. For more information, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-355.html.
    Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for multidisciplinary research on HIV/AIDS and aging through the R21 Exploratory/Developmental Research Grant program. This initiative invites applications that aim to enhance the understanding of the biological, clinical, and socio-behavioral aspects of aging in the context of HIV infection, with specific objectives to improve prevention, testing, treatment strategies, and management of HIV-related health issues in diverse populations, particularly older adults aged 70 and above. The grant provides funding of up to $275,000 for a two-year period, with key submission dates starting April 4, 2024, and a closing date for applications set for January 7, 2027. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)" aimed at supporting innovative research at the intersection of HIV and substance use. This initiative seeks proposals that address critical gaps in understanding and improving health outcomes for individuals living with HIV who also face substance use disorders, requiring detailed research plans and preliminary data from both individual researchers and research teams. NIH plans to allocate approximately $3 million annually for three to five awards over three years, with applications due by January 11, 2025, and a strong emphasis on enhancing diverse perspectives through an inclusion plan. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-024.html.
    Mechanistic Exploration of Therapeutic Targets and Treatable Traits to Improve CNS Outcomes in People with HIV
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Mechanistic Exploration of Therapeutic Targets and Treatable Traits to Improve CNS Outcomes in People with HIV." This initiative aims to support research that identifies modifiable targets and mechanisms to alleviate central nervous system (CNS) complications in individuals living with HIV, leveraging patient-derived data and innovative model platforms. The program emphasizes the importance of understanding the multifactorial nature of CNS dysfunction and seeks to accelerate the development of effective interventions through clinical studies or pre-clinical models. The estimated total funding for this program is $3 million, with approximately six awards expected. Interested applicants, particularly those with expertise in systems biology and translational neurobiology, should prepare for the upcoming Notice of Funding Opportunity (NOFO), with applications anticipated to open in September 2025. For further inquiries, potential applicants can contact Vasudev R Rao at vasudev.rao@nih.gov or by phone at 301-825-3259.
    Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the grant opportunity titled "Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK." This funding initiative aims to support innovative pilot research projects that explore the biological, behavioral, and social mechanisms related to HIV pathogenesis, particularly focusing on comorbidities and complications affecting organs and tissues relevant to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The research is expected to enhance understanding of the interplay between HIV and associated health issues, with a funding cap of $275,000 over two years for successful applications. Interested applicants, including higher education institutions and various nonprofit organizations, should note that the application deadlines begin in April 2025, with the final submission date set for January 7, 2028. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Institute on Deafness and Other Communication Disorders (NIDCD), has announced a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)." This grant aims to stimulate innovative research addressing critical issues related to communication disorders—such as hearing, balance, taste, smell, voice, speech, and language—specifically for individuals living with HIV/AIDS. The initiative encourages multidisciplinary collaborations and supports low-risk clinical trials that do not require FDA oversight, with a total funding limit of $275,000 for two-year projects, and no more than $200,000 in any single year. Interested applicants, including various academic institutions and nonprofits, must submit their proposals by January 7, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD," aimed at stimulating research related to HIV/AIDS and communication disorders. This initiative encourages applications that address high-priority research areas defined by the NIH Office of AIDS Research, focusing on the impact of HIV on hearing, balance, taste, smell, voice, speech, and language, with a budget limit of $275,000 for a two-year project period. Eligible applicants include a diverse range of institutions and organizations, and only low-risk clinical trials that do not require FDA oversight will be supported. Interested parties can find more information and application details at the NIH grants website, with deadlines for submissions ranging from May 2025 to January 2028.
    Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)" aimed at enhancing research on the intersection of HIV and aging. The program seeks applications that focus on improving the understanding of biological, clinical, and socio-behavioral aspects of aging in the context of HIV infection, as well as developing better methods for testing, preventing, and managing HIV-related health issues among older populations. This initiative is particularly significant given the projected increase in the prevalence of HIV among older adults, which is expected to rise from 53% to over 70% by 2030, highlighting the urgent need to address the complex challenges associated with aging and HIV. Interested applicants can submit proposals until January 7, 2027, with no budget limits as long as they align with project needs; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-354.html.